Travecta Therapeutics
  • Discovery Platform
  • Pipeline
  • Insights
    • Recent News
    • Scientific Presentations & Publications
  • About
  • Contact
Select Page

News

News

Latest Posts

  • Travecta Therapeutics Appoints Jerold Chun, M.D., Ph.D. to its Scientific Advisory Board

    Travecta Therapeutics Appoints Jerold Chun, M.D., Ph.D. to its Scientific Advisory Board

    by admin - November 9, 2020
  • Travecta Therapeutics announces it has closed its oversubscribed Series A Round at $27 Million

    Travecta Therapeutics announces it has closed its oversubscribed Series A Round at $27 Million

    by admin - June 11, 2020
  • Travecta Therapeutics Presents at Ventures Day Singapore in 2020, on February 7th

    Travecta Therapeutics Presents at Ventures Day Singapore in 2020, on February 7th

    by admin - February 7, 2020
  • Travecta showcases its novel blood-brain barrier transport platform in New York, USA

    Travecta showcases its novel blood-brain barrier transport platform in New York, USA

    by admin - April 24, 2019
  • Travecta Therapeutics presents corporate updates at TKS 1 Investor Day in Singapore

    Travecta Therapeutics presents corporate updates at TKS 1 Investor Day in Singapore

    by admin - February 7, 2019
Travecta Therapeutics Appoints Jerold Chun, M.D., Ph.D. to its Scientific Advisory Board

Travecta Therapeutics Appoints Jerold Chun, M.D., Ph.D. to its Scientific Advisory Board

Nov 9, 2020

Dr. Chun to help lead the biopharmaceutical company toward its first human trial for a non-opioid pain therapeutic NEW YORK and SINGAPORE – November 9, 2020 – Travecta Therapeutics, a...

read more
Travecta Therapeutics announces it has closed its oversubscribed Series A Round at $27 Million

Travecta Therapeutics announces it has closed its oversubscribed Series A Round at $27 Million

Jun 11, 2020

Travecta Therapeutics, a biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, announces today it has raised an additional $12 million...

read more
Travecta Therapeutics Presents at Ventures Day Singapore in 2020, on February 7th

Travecta Therapeutics Presents at Ventures Day Singapore in 2020, on February 7th

Feb 7, 2020

WE HAD ANOTHER SUCCESSFUL VENTURES DAY IN SINGAPORE. Travecta Therapeutics presented its technology and showcased its achievements at another SPRIM’s Ventures Day in Singapore. Following our three...

read more
Travecta showcases its novel blood-brain barrier transport platform in New York, USA

Travecta showcases its novel blood-brain barrier transport platform in New York, USA

Apr 24, 2019

Travecta Therapeutics is one of eight companies that will present at SPRIM’s quarterly Ventures Day meeting in New York on April 24. The event will provide insights into the latest innovations and...

read more
Travecta Therapeutics presents corporate updates at TKS 1 Investor Day in Singapore

Travecta Therapeutics presents corporate updates at TKS 1 Investor Day in Singapore

Feb 7, 2019

Travecta Therapeutics, an emerging biotech company utilizing its novel Blood-Brain Barrier (BBB) Transport Platform to develop a proprietary pipeline of molecules that treat disorders of the central...

read more
Tackling the blood-brain barrier: Duke-NUS discovery leads to startup Travecta

Tackling the blood-brain barrier: Duke-NUS discovery leads to startup Travecta

Mar 22, 2018

Travecta Therapeutics Pte Ltd. is the latest startup to join Singapore’s biotech block. The newly formed drug discovery company is based on intellectual property derived from discoveries made at...

read more
Duke-NUS commercializes discovery to deliver therapeutics across blood brain barrier

Duke-NUS commercializes discovery to deliver therapeutics across blood brain barrier

Mar 1, 2018

Intellectual property (IP) derived from discoveries made at Duke-NUS Medical School (Duke-NUS) have been licensed to a newly formed biotech start-up, Travecta Therapeutics Pte Ltd, a Singapore-based...

read more

Travecta Therapeutics

Developing a proprietary pipeline of molecules that cross the Blood Brain Barrier to treat disorders of the central nervous system.

Company

  • Discovery Platform
  • Pipeline
  • About
  • Contact

Links

  • Recent News
  • Scientific Presentations & Publications

Newsletter

Join our mailing list for updated news and promotions.

© 2020 Travecta Therapeutics. Web Design by Martin Santoso